Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-11-10FDA Approved: FINGOLIMOD — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma's original application for fingolimod hydrochloride (Fingolimod HCl), a generic version of the MS drug fingol…
-
FDA approval · 2021-11-03FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for Rebif (interferon beta-1a) submitted by EMD Serono, Inc.
-
FDA label_change · 2021-11-03FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Betaseron (interferon beta-1b) to update the product labeling.
-
FDA approval · 2021-11-03FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for AVONEX (interferon beta-1a).
-
FDA approval · 2021-11-03FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for the Plegridy Pen auto-injector for peginterferon beta-1a, submitted by Biogen. The action approv…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 trial update evaluating safety and efficacy of orally administered laquinimod versus placebo in relapsing-remitting multiple scleros…
-
FDA approval · 2021-10-28FDA Approved: PONVORY — Supplemental Application (Janssen Pharmaceuticals, Inc)
FDA approved Janssen's supplemental application for PONVORY (ponesimod), authorizing changes to its labeling.
-
FDA approval · 2021-09-29FDA Approved: DALFAMPRIDINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for dalfampridine from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
Clinical trial assessing teriflunomide (Aubagio) impact on cognitive and vocational outcomes in multiple sclerosis has completed with result…
-
FDA approval · 2021-09-22FDA Approved: BACLOFEN — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for baclofen from Chartwell RX, LLC, under ANDA077241, indicating regulatory approval of this supple…
-
FDA approval · 2021-09-15FDA Approved: DALFAMPRIDINE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories, LLC's supplemental application for dalfampridine, resulting in a generic dalfampridine product being appro…
-
FDA approval · 2021-09-15FDA Approved: DALFAMPRIDINE — Supplemental Application (Micro Labs Limited)
The FDA approved a supplemental application for dalfampridine from Micro Labs Limited (ANDA210158), enabling a generic version to be markete…
-
FDA approval · 2021-09-10FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Mayzent (siponimod) by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2021-09-08FDA Approved: DALFAMPRIDINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA has approved a supplemental application for dalfampridine from Sun Pharmaceutical Industries, Inc. This approval updates the regulat…
-
FDA approval · 2021-09-08FDA Approved: DALFAMPRIDINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for dalfampridine from Actavis Pharma, Inc., resulting in the approval of a generic dalfampridine pr…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Tecfidera and the Gut Microbiota [Phase 4]
Phase 4 clinical trial update on Tecfidera (dimethyl fumarate) and its relationship with the gut microbiota in relapsing multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients [Phase 4]
Phase 4 study evaluation of [18F]Florbetapir PET feasibility for assessing multiple sclerosis; completed with results posted.
-
FDA approval · 2021-08-24FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Mayzent (siponimod) filed by Novartis Pharmaceuticals Corporation. The action updates the dr…
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: A Positive Psychology Intervention for Patients With Multiple Sclerosis [NA]
A completed clinical trial assessing a positive psychology intervention for patients with multiple sclerosis; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Imatinib for Multiple Sclerosis (MS) Relapses [Phase 2]
Phase 2 clinical trial evaluating imatinib for multiple sclerosis relapses is in an unknown status.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Visual Reconstitution Therapy After Optic Neuritis [Phase 2]
Phase 2 trial update on visual reconstitution therapy for optic neuritis, with conditions including optic neuritis and multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Sunphenon in Progressive Forms of Multiple Sclerosis [Phase 2, Phase 3]
Clinical trial update for Sunphenon in progressive forms of multiple sclerosis, encompassing Phase 2 and Phase 3 completion.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) [Phase 2, Phase 3]
Clinical trial MOVING evaluating modification of visual outcomes after optic neuritis in CIS or MS using Gilenya; terminated study phase 2/3…
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue [Phase 1, Phase 2]
A clinical trial investigating microglial activation and norepinephrine transporter abnormalities as factors in multiple sclerosis-related f…
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab [Phase 4]
A Phase 4 pilot study evaluating the biological effects of a planned 12-week interruption of natalizumab in patients with relapsing forms of…